Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 4:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,125 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Arthritis Rheumatoid Clear all

Conditions: Arthritis, Rheumatoid
Interventions: BI 695500; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 26 more

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Scipher Medicine; Industry
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 30
States / cities: Chandler, Arizona • Covina, California • Hemet, California + 27 more

Conditions: Arthritis, Rheumatoid, Medication Adherence
Interventions: Motion sensors and daily online assessments; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Long QT Syndrome, Connective Tissue Diseases, Rheumatoid Arthritis
Interventions: Prednisone; Drug
Lead sponsor: Narrows Institute for Biomedical Research; Other
Eligibility: 18 Years to 89 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 78
States / cities: Tuscaloosa, Alabama • Peoria, Arizona • Scottsdale, Arizona + 68 more

Conditions: Avascular Necrosis, Osteoarthritis, Inflammatory Arthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Interventions: Continuum Metal on Polyethylene Acetabular System; Device
Lead sponsor: Zimmer Biomet; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 2
States / cities: Fremont, California • Denver, Colorado

Conditions: Rheumatoid Arthritis, Endothelial Dysfunction
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Arthritis, Rheumatoid Arthritis
Interventions: Mobile Application, Population Management System; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 107
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more

Conditions: Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
Interventions: Baricitinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rheumatoid Arthritis
Interventions: RA PRO Dashboard; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rheumatoid Arthritis
Interventions: suspension IR, CR 1, CR 2, CR 3; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Juvenile Idiopathic Arthritis
Interventions: Rilonacept; Biological
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Months to 19 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Rheumatoid Arthritis
Interventions: strength training; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 90 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Sjogren's Syndrome
Interventions: Placebo, Nipocalimab, Standard of Care Treatment; Other · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 25
States / cities: Anniston, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib, Rosuvastatin, Simvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Arthritis, Rheumatoid
Interventions: GSK1827771, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Evansville, Indiana • Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: PDA001, Vehicle Controlled Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more

Conditions: Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions: Fish Oil, Vitamin D, placebo pill; Drug · Dietary Supplement · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Leflunomide, Methotrexate, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 144
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Rheumatoid Arthritis
Interventions: H.P. Acthar gel; Drug
Lead sponsor: Iraj Sabahi Research Inc.; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Pleasanton, California • Turlock, California

Conditions: Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis
Interventions: Maxim® Knee System with Removable Molded Polyethylene Tibia, Regular Maxim® Knee System; Device
Lead sponsor: Biomet Orthopedics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Warsaw, Indiana

Conditions: Rheumatoid Arthritis (RA)
Interventions: AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo; Drug
Lead sponsor: SynAct Pharma Aps; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania

Search by objective public record fields.

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

A Clinical Utility Study of PrismRA for Rheumatoid Arthritis

Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study

Novel Form of Acquired Long QT Syndrome

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) Study

Atherosclerosis in Rheumatoid Arthritis

A Novel Mobile App & Population Management System to Manage Rheumatoid Arthritis Flares

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Incorporating PRO Data Into RA Clinical Encounters Using Health IT

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults

The Effects of a 16-Week Individualized, Intensive Strength Training Program in Patients With Rheumatoid Arthritis

Perioperative Flare in RA: Characterization of Clinical and Biological Features

A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

A Phase I Rheumatoid Arthritis Study in Healthy Volunteers

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

Maxim® Knee Pop-Top® Tibia vs. Regular Maxim® Knee Tibia

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis